After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Cerevel Therapeutics Holdings Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Cerevel Therapeutics Holdings Inc is $7.65B. A total of 1.22 million shares were traded on the day, compared to an average of 1.49M shares.
In the most recent transaction, COLES N ANTHONY sold 50,000 shares of CERE for 42.33 per share on Apr 01 ’24. After the transaction, the Director now owns 15,638 company shares. In a previous transaction on Mar 04 ’24, COLES N ANTHONY sold 50,000 shares at 41.01 per share. CERE shares that Director owns now total 15,638.
Among the insiders who sold shares, COLES N ANTHONY disposed of 50,000 shares on Feb 29 ’24 at a per-share price of $41.16. This resulted in the Director holding 15,638 shares of CERE after the transaction. In another insider transaction, COLES N ANTHONY sold 2,506 shares at $41.54 per share on Feb 07 ’24. Company shares held by the Director now total 15,638.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CERE has a high of $43.59 and a low of $19.59.
As of this writing, CERE has an earnings estimate of -$0.61 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.49 per share and a lower estimate of -$0.76. The company reported an EPS of -$0.61 in the last quarter, which was 3.20% higher than expectations of -$0.63.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CERE’s latest balance sheet shows that the firm has $565.69M in Cash & Short Term Investments as of fiscal 2021. There were $36.55M in debt and $42.54M in liabilities at the time. Its Book Value Per Share was $3.71, while its Total Shareholder’s Equity was $578.73M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CERE is Buy with a score of 3.36.
